HomeComparePIRS vs ADC

PIRS vs ADC: Dividend Comparison 2026

PIRS yields 14.71% · ADC yields 4.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ADC wins by $126.5K in total portfolio value· pulled ahead in Year 7
10 years
PIRS
PIRS
● Live price
14.71%
Share price
$13.60
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$52.5K
Annual income
$3,650.55
Full PIRS calculator →
ADC
Agree Realty Corporation
● Live price
4.13%
Share price
$74.97
Annual div
$3.10
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$178.9K
Annual income
$80,797.29
Full ADC calculator →

Portfolio growth — PIRS vs ADC

📍 ADC pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPIRSADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PIRS + ADC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PIRS pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PIRS
Annual income on $10K today (after 15% tax)
$1,250.00/yr
After 10yr DRIP, annual income (after tax)
$3,102.97/yr
ADC
Annual income on $10K today (after 15% tax)
$351.36/yr
After 10yr DRIP, annual income (after tax)
$68,677.70/yr
At 15% tax rate, ADC beats the other by $65,574.73/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PIRS + ADC for your $10,000?

PIRS: 50%ADC: 50%
100% ADC50/50100% PIRS
Portfolio after 10yr
$115.7K
Annual income
$42,223.92/yr
Blended yield
36.49%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

PIRS
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
-1.7
Piotroski
1/9
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+8.1% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PIRS buys
0
ADC buys
0
No recent congressional trades found for PIRS or ADC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPIRSADC
Forward yield14.71%4.13%
Annual dividend / share$2.00$3.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$52.5K$178.9K
Annual income after 10y$3,650.55$80,797.29
Total dividends collected$25.1K$156.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: PIRS vs ADC ($10,000, DRIP)

YearPIRS PortfolioPIRS Income/yrADC PortfolioADC Income/yrGap
1$12,171$1,470.59$10,990$580.36+$1.2KPIRS
2$14,695$1,672.70$12,301$860.26+$2.4KPIRS
3$17,611$1,887.56$14,104$1,298.62+$3.5KPIRS
4$20,958$2,114.15$16,691$2,008.16+$4.3KPIRS
5$24,777$2,351.33$20,580$3,205.09+$4.2KPIRS
6$29,109$2,597.87$26,754$5,330.02+$2.4KPIRS
7← crossover$33,999$2,852.44$37,196$9,345.14$3.2KADC
8$39,493$3,113.67$56,244$17,523.09$16.8KADC
9$45,637$3,380.17$94,286$35,736.21$48.6KADC
10$52,483$3,650.55$178,949$80,797.29$126.5KADC

PIRS vs ADC: Complete Analysis 2026

PIRSStock

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; and immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers. The company also develops PRS-344/S095012, a bispecific anticalin-antibody fusion protein targeting 4- 1BB and PD-L1 for immuno-oncology diseases that is in phase 1 clinical trial; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.

Full PIRS Calculator →

ADCREIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →
📬

Get this PIRS vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PIRS vs SCHDPIRS vs JEPIPIRS vs OPIRS vs KOPIRS vs MAINPIRS vs NNNPIRS vs EPRTPIRS vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.